In 2006 the two radiologists, Thomas and Ingvar, discovered a potential to use liquid oat cream as a food-based negative contrast agent.
They contacted Prof. Rickard Öste and Prof. Björn Bergenståhl (both Lund University) and the work begun!
After almost ten years of development and research the first concept of per-oral, food-based negative contrast agent was presented and ready for further clinical evaluation in 2015.
In 2016 the first clinical trial on 25 healthy subjects was performed at Malmö University Hospital (SUS). In 2017 we apply for phase II study that will be conducted at the same hospital.
The Lument Timeline
2006 – Vision of invention
Thomas Fork brought up the idea of developing a true negative bowel contrast agent for computer tomography (CT) with a quality comparable to MR-images. Among the specs were that the agent should be food-based, pleasant to drink, and with no side effects
2009 – Lument AB
Lument AB was founded for the development of the novel negative contrast agent
March 2016 – Pre-clinical Trial
Positive results in feasibility studies in vitro digestive tests
April to October 2016 – Pilot Trial
Promising results from an in vivo pilot test with 25 healthy volunteers.
- Excellent contrast
- Acceptable palatability
- No important side effects
- Positive external referees
February 2017 – Lumentin®
Lumentin® registered for the EU trade mark.
Pending: US, Canada, Switzerland, China, UK, Hong Kong and Japan
March 2017 – Patent Pending
Product production filed to be patented.
November 2017 – Phase II Clinical Trial
Application process is, as of June 2017, ongoing.